SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Is DaVita's Stock Performance Compared to Other Health Care Services Stocks?

DaVita has underperformed the health care services industry this year, and analysts are cautious about the stock’s prospects.

How Is Molina Healthcare's Stock Performance Compared to Other Health Care Services Stocks?

Despite Molina Healthcare’s recent underperformance relative to its industry peers, analysts remain moderately optimistic about the stock’s prospects.

Are Wall Street Analysts Bullish on Quest Diagnostics Stock?

Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Is Wall Street Bullish or Bearish on Henry Schein Stock?

Henry Schein has trailed the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on its future performance.

HCA Healthcare Stock: Is Wall Street Bullish or Bearish?

HCA Healthcare has lagged behind the broader market this year, yet analysts maintain a fairly positive outlook on its future performance.

Are Wall Street Analysts Predicting The Cigna Group Stock Will Climb or Sink?

The Cigna Group observed a notable drop in earnings in the recent quarter and has continued to underperform other healthcare services stocks over the past year. Yet, analysts remain strongly bullish on the stock’s prospects.

Are Wall Street Analysts Predicting Cardinal Health Stock Will Climb or Sink?

Cardinal Health has observed a notable surge in stock prices recently and received several ratings upgrades shifting the consensus to a "Strong Buy."

Do Wall Street Analysts Like Centene Stock?

Although Centene has lagged behind the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock's growth potential.

Shares of The Cigna Group traded about 0.8% lower in volatile action Monday morning as Wall Street analysts continued to slash price targets following last week's disappointing fourth-quarter earnings miss.However, retail sentiment remained strong, indicating traders are betting on a rebound.According to The Fly, TD Cowen analyst Charles Rhyee lowered his price target on Cigna to $380 from $391 while maintaining a 'Buy' rating, citing continued upside from strong specialty trends despite the weak quarter.Piper Sandler analyst Jessica Tassan cut her price target to $348 from $394, keeping an 'Overweight' rating. The brokerage attributed Cigna's Q4 earnings miss to a rise in high-cost claimants within its Stop-Loss segment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CI_sentiment_and_message_volume_on_Feb_3_premarket_1c05b0067d.png" alt="CI sentiment and message volume on Feb 3 premarket.png" width="1318" height="324"><figcaption>CI sentiment and message volume on Feb 3 as of 10:30 am ET | source: Stocktwits</figcaption></figure>Despite the fresh price-target cuts, sentiment on Stocktwits remained 'extremely bullish,' suggesting retail investors have been buying the dip.Cigna shares have climbed more than 5% since last week's earnings report, with many retail traders arguing the stock is oversold and offers an attractive entry point.<stembedurl>https://stocktwits.com/Mackman15/message/602301602</stembedurl><stembedurl>https://stocktwits.com/healthcareguru/message/602261078</stembedurl>According to Koyfin data, the health insurer's stock trades 25% below analysts' average price target of $367.87. Shares are up 4.6% year-to-date.In a separate announcement Monday, Cigna said it will begin linking executive compensation to customer satisfaction, pledging to streamline access to care by making the process "simpler, easier, and faster."&nbsp;The company plans to implement governance changes to improve accountability and will publish an annual customer transparency report starting next year.The move comes weeks after UnitedHealth CEO Brian Thompson was shot and killed in New York City, reigniting debates over the state of U.S. health care.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Cigna Corporation logo is displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

Cigna Stock Slips On More Price-Target Cuts After Weak Q4, But Retail Bets On A Rebound

Shares have climbed more than 5% since last week's earnings report, with many retail traders arguing the stock is oversold and offers an attractive entry point.

Equity

Shares have climbed more than 5% since last week's earnings report, with many retail traders arguing the stock is oversold and offers an attractive entry point.


Shares of Quest Diagnostics, Inc. jumped nearly 6% to hit levels last seen toward the end of November, driven by upbeat quarterly earnings.The stock is on course to notch its best intraday session in over three months.The company reported fourth-quarter (Q4) adjusted earnings per share (EPS) of $2.23, beating the consensus estimate of $2.18, while revenue came in at $2.62 billion, surpassing expectations of $2.58 billion."In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability," said CEO Jim Davis.He added that Quest completed eight acquisitions in 2024, including LifeLabs in Canada, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.Looking ahead, Quest sees full-year adjusted EPS between $9.55 and $9.80, compared to the consensus estimate of $9.72.&nbsp;The company expects FY25 revenue in the range of $10.7 billion to $10.85 billion, above the consensus of $10.67 billion.&nbsp;It also anticipates generating $1.45 billion in cash from operations and plans capital expenditures of $500 million for the year.Quest’s board of directors has authorized a 6.7% increase in its quarterly dividend from $0.75 to $0.80 per share, or $3.20 annually, effective with the dividend payable on April 21 to shareholders of record on April 7.&nbsp;The company said it has raised its dividend annually since 2011.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DGX_sentiment_and_message_volume_Jan_30_cbb46c7261.png" alt="DGX sentiment and message volume Jan 30.png" width="1318" height="324"><figcaption>DGX sentiment and message volume Jan 30 as of 12:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Quest turned ‘extremely bullish,’ with message volume soaring.<stembedurl>https://stocktwits.com/GettnFibbywIT/message/602106527</stembedurl>The stock has generated significant attention on the platform, with message volume tripling over the past three months.&nbsp;<a href="https://stocktwits.com/symbol/DGX">Quest</a> rose to prominence during the COVID-19 pandemic, supplying virus testing kits at scale. As infections waned, the company pivoted back to its core business.&nbsp;Last year, it struck a deal to acquire LifeLabs, a leading Canadian community laboratory services provider, from pension fund OMERS for approximately C$1.35 billion ($985 million), including net debt.Shares of Quest have gained more than 26% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Quest Diagnostics logo of a US clinical laboratory is displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Grows

Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers.

SPDR Series Trust - SPDR S&P Health Care Services ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$105.28
Prev Close	$104.77
Open	$104.70
Dividend Yield	N/A
50-Day Moving Average	$100.63
Beta	N/A
Avg. Volume	4,289.43
PE Ratio	N/A

52-Week High	$106.26
52-Week Low	$87.64
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

XHS
SPDR S&P Health Care Services ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XHS News

XHSSPDR S&P Health Care Services ETF